Exenatide may aggravate moderate diabetic renal impairment: A case report

British Journal of Clinical Pharmacology

Volumn 66, Issue 4, 2008, Pages 568-569

  Johansen, Odd Erik ^a,b   Whitfield, Rolf ^b  

^a Medical Department   (Norway)

^b VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ALLOPURINOL; BIPHASIC INSULIN; EXENDIN 4; FUROSEMIDE; INSULIN ASPART; LOSARTAN POTASSIUM; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SPIRONOLACTONE;

AGED; CASE REPORT; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; GOUT; HUMAN; KIDNEY DISEASE; LETTER; MALE; METABOLIC BONE DISEASE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; TREATMENT OUTCOME; TREATMENT RESPONSE;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PEPTIDES; VENOMS;

EID: 51649107392     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03221.x     Document Type: Letter

References (6)

1. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007 64: 317 27.
2. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16: 31 41.
3. Obrador GT, Arora P, Kausz AT, Ruthazer R, Pereira BJ, Levey AS. Level of renal function at the initiation of dialysis in the U.S. end-stage renal disease population. Kidney Int 1999 56: 2227 35.
4. Datapharm Communications Ltd. Electronic medicines compendium. Available at http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc. asp&documentid=19257 (last accessed 24 April 2008).
5. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007 13: 444 50.
6. Sheffield CA, Kane MP, Busch RS. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. Pharmacotherapy 2007 27: 1449 55.